Phages vs. Nosocomial Infections Phage Biotech Ltd. develops and produces bacteriophages anti-bacterials which destroy antibiotic-resistant bacterial concentrations rapidly, safely and effectively

1
Phages vs. Nosocomial InfectionsPhage
Biotech Ltd. develops and produces bacteriophages
anti-bacterials which destroy antibiotic-resistant
bacterial concentrations rapidly, safely and
effectively
2
Nosocomial Infections

• Nosocomial infections result from treatment in a
  hospital, but are
• secondary to the patient's original condition.
  Such hospital-acquired
• infections are even more alarming in the 21st.
  century as antibiotic
• resistance spreads.
• Reasons
• Hospitals house large numbers of people who are
  sick and whose immune system are often in a
  weakened state
• Increased use of outpatient treatment means that
  people who are in the hospital are sicker on
  average
• Medical staff move from patient to patient,
  providing a way for pathogens to spread
• Many medical procedures bypass the body's natural
  protective barriers
• Routine use of anti-microbial agents in hospitals
  creates selection pressure for the emergence of
  resistant strains

3
Epidemiolgy

• In the US and Europe, an estimated 5-10 of
  patients are expected to develop an infection
  during their hospital stay. The four main types
  of infections that occur within the hospital
  setting are urinary tract infections, hospital
  acquired pneumonia, surgical site infections and
  blood-stream infections, accounting for
  approximately 35, 15, 14 and 10 respectively.
  (Datamonitor)
• Over 15 of which result in death
• Annual costs in the US exceed 11 billion
• Nosocomial infections contribute to over 100,000
  deaths in the US

4
????????

• "????? VRE????? ???????? 20 ????? ?????
  ??????". YNET 28.01.05
• "????? ????? ????? ???? ????? ????? ??????? ?????
  ?????? VRE ????? ???? ???????????". YNET
  30.01.05
• "????? ?????? ?? ???? ?? ?????? ????? ???? ?????,
  ???? ????? ???? ?????? ??? ???? ???? ???? ??
  ????? ????". YNET 17.4.05
• "???? ?????? ????, ??? ????? ?????? ????? ?????
  VRE ????? 5 ?????". WALLA 3.2.06
• "??????? ?????? ????? ??? ??????? ?? ????? VRE
  ???? ?????? ????? ?????, ????? ?????? ??? ?????
  ?????????". NRG 7.4.06
• "????? ???? ??????? ?????? ???? ?????? ????
  ?????? ????? ????? ?????? ?? ????? VRE ????
  ????????????". NRG 23.5.06

5
Hospital Super Bugs

• MRSA
• VRE
• Pseudomonas aeruginosa
• Clostridium
• Klebsiela
• Acinetobacter
• E.coli
• Proteus

6
Market Trends

• Antibiotic-resistance is accelerating and
  expanding
• Antibiotics market is stagnating
• Last ethical antibiotics expire and Pharma is
  dumping off its antibiotic operations
• No alternative anti-bacterials in pipeline
• Conventional sanitation accelerates
  hospital-acquired bacteria
• Increase in nosocomial infections, mortality, and
  costs
• Shift toward ecological methods in microbial
  control

7
Phage Technology

• Bacteriophages are ubiquitous bacterial viruses
  that can only attach to, replicate in, and in the
  process, kill specific bacteria
• Phage Biotech's proprietary process enables the
  rapid production of high-volume, highly
  concentrated bacteriophage suspensions for
  de-contamination and treatment

8
Phage Structure
Phage Biotech Ltd. Business Plan
9
Phage Function
Bacteriophage attaches to target bacterial cell
and injects the genetic material
Phage replicates
Bacterial cell disintegrates, and new phages
released to infect other bacterial cells
Phage Biotech Ltd. Business Plan
10
The Phage Advantage

• Phages thrive in the presence of bacteria, and
  die out in their absence
• Phages action is specific, and does not harm
  vital micro flora
• Phages may be used both preventively, and in the
  treatment of ongoing infections
• Phages present the only viable alternative and,
  potentially, the last resort for the treatment of
  antibiotic-resistant infections
• Phage-bacteria co-evolution provides for an
  inexhaustible reservoir of virulent phages

11
The Product

• A liquid suspension (108 PFU) of purified lytic
  bacteriophages with strain-specific or polyvalent
  anti-bacterial activity.
• Application by surface spraying 1L/1,000 SQM.
• Reduction of bacterial titer by several logs in
  hours.

12
The Benefits

• Patients Benefits
• Hospitalized patients and the community will
  benefit
• from a reduced exposure to common
  hospital-acquired
• infections.
• Hospitals Benefits
• Less sanitation and treatment costs
• less closures, quarantines, evacuations
• Less costly control and preventive measures
• Less operational costs
• less liability lawsuits
• Less adverse publicity and an improved reputation

13
The Market

• Therapeutics phage medicines will gradually
  replace ineffective antibiotics in the 150
  billion anti-bacterials market.
• Sanitation phage de-contaminants are critically
  needed for the 70 billion hospitals sanitation
  market.

14
Alternatives

• Antibiotics ineffective, banned or restricted
• Vaccines - few, expensive and often impractical
• Sanitation Selective pressure favoring Super
  Bugs
• Probiotics - partial preventive measures

15
Management

• Asher Wilf Founder and CEO
• Ph.D. Sergey Bujanover Director, Chief
  Scientist (Microbiology, Virology)
• Prof. Natalia N. Voroshilova, M.D.
  (Immunopreparat) Scientific Advisor (Phage
  Therapy)
• Scientific Advisory Board
• Prof. Gerald Cohen (Tel Aviv University)
  Scientific Advisor (Microbiology, Phages, Drug
  targeting, Antibacterials)
• Prof. Alik Honigman (Hebrew University)
  Scientific Advisor (Microbiology Phages,
  Virology, Genetical engineering)
• Prof. Ethan Rubinstein, M.D.(Shiba-Tel Hashomer
  Medical Center) Scientific Advisor (Infectious
  diseases).
• Prof. Zeev Handzel, M.D. (Kaplan Hospital)
  Scientific Advisor (Immunology and Pediatrics).
• Prof. Stephen T. Abedon (OSU) Scientific
  Advisor (Microbiology, Phage Ecology)
• Strategic collaboration Immunopreparat, Ufa,
  Russia

16
The Core Technology

• Phage Biotech Ltd. has developed a proprietary
  cost-effective
• process enabling low-end, high volume
  applications such as feed
• additives, as well as an efficient pharmaceutical
  grade
• purification process (US Patent No.
  US/IL03/01041).
• Technology Features
• Low cost production infrastructure and equipment
• Non-fermentation, low volume, high titer process
• Optimal process control
• No contamination
• Additional IP assets
• Phages collections
• Proprietary formulations
• Wild phages isolation and matching algorithms

17
Regulation

• The first ever landmark FDA approval has been
  granted in August 2006 to a Listeria phages food
  additive.
• An EPA approval for the same product as a surface
  decontaminant has been granted.
• An approval for similar products targeting E.coli
  and Salmonella is imminent.

18
The Model

• Setting up a dedicated clinical phage lab
• Isolating phages in-situ and acquisition from
  collections
• Setting up cultures and phages libraries
• Selecting virulent phages against clinical
  isolates
• Producing purified lysates

19
Products and services

• Bacterial decontamination products and services
  for hospitals
• Phage Medicines
• Phage Therapy Treatments
• Contract RD
• Contract Production
• Outlicensing